Sepsis without borders: Why Europe–China collaboration is essential for precision critical care Authors: Ignacio Martin-Loeches, Yan Kang, Jean-Louis Teboul Published: 2026 Introduction Sepsis remains one of the most complex and heterogeneous syndromes in modern medicine. Despite major advances in early recognition, resuscitation strategies, antimicrobial therapy, and organ support, outcomes remain highly variable, and many therapeutic interventions have failed to translate across settings. Recent expert opinion has reinforced the concept that sepsis should be understood as a biologically heterogeneous syndrome arising from a dysregulated host response to infection, rather than as a single disease entity, with important implications for research and clinical practice.[1] In this context, sepsis research confined to single regions risks producing incomplete or non-generalizable insights. Closer collaboration between Europe and China offers a unique opportunity to address this limitation and move sepsis care toward a truly global, precision-oriented model. This paper aims to examine why closer Europe–China collaboration is essential to advance precision sepsis care, by integrating complementary clinical, biological, and technological strengths to overcome the limitations of regionally siloed research and improve the generalizability of sepsis phenotyping and therapeutic strategies. Complementary Strengths: Maturity vs. Scale and Speed European critical care has long been characterized by mature healthcare systems, structured intensive care unit (ICU) networks, and harmonized clinical pathways. Many European countries benefit from universal healthcare coverage, well-established sepsis protocols, antimicrobial stewardship programs, and national or transnational registries. These conditions favor high methodological rigor, reproducibility, and careful phenotype definition. European research has been particularly effective at refining standards of care, generating high-quality observational data, and conducting multicenter trials embedded in routine clinical practice. Large European cohort studies have also documented temporal trends in sepsis outcomes and contributed substantially to guideline development. China, by contrast, has undergone rapid expansion in critical care capacity over the past 2 decades. The scale of ICU services, patient volume, and workforce growth is unparalleled. National multicenter surveys have demonstrated a substantial burden of sepsis and septic shock across Chinese ICUs, with marked heterogeneity in case mix, management strategies, and outcomes. This scale enables rapid accumulation of clinical data, including rare sepsis trajectories and uncommon complications that may be underrepresented in smaller cohorts. In parallel, China has emerged as a global leader in digital health infrastructure, artificial intelligence (AI), and real-time clinical data capture.[2] Large electronic health record systems, bedside integration, and AI-driven analytics are increasingly embedded into ICU workflows, enabling early risk stratification and continuous learning at a pace difficult to replicate elsewhere.[3] Importantly, this expansion should not be interpreted only in terms of volume or technological capacity. Over the same period, Chinese critical care medicine has undergone substantial clinical maturation. Major academic centers have progressively adopted structured ICU protocols, sepsis bundles, antimicrobial stewardship practices, and international guideline-based approaches.[4,5] In parallel, national and regional efforts have strengthened training, quality improvement, and multicenter collaboration. The development of large critical care research networks, including the China Critical Care Clinical Trials Group, illustrates the transition from isolated institutional experience toward coordinated, multicenter investigation.[6] Therefore, China’s contribution to global sepsis research is not limited to patient numbers or AI infrastructure, but increasingly includes high-quality clinical delivery, pragmatic implementation capacity, and rapidly evolving research organization. These differences should not be viewed as competing models. Rather, they are complementary. Europe brings depth, standardization, and methodological robustness; China contributes volume, speed, and technological innovation. Together, they create an ecosystem capable of discovering, validating, and implementing sepsis insights at scale (Table 1). Table 1Complementary strengths and population-level differences relevant to sepsis research in Europe and China.Table 1: dummy alt textDomainEuropeChinaImplications for sepsis researchHealthcare system maturityLong-established ICU networks, harmonized protocolsRapidly expanding ICUs, increasing standardization, variable regional resourcesComparison of protocol-driven vs. high-variability systemsPatient volumeModerate, stableVery highIdentification and validation of rare phenotypesResearch infrastructureMature registries and trial networksExpanding multicenter research networks and pragmatic observational studiesInternal validity combined with scalabilityDigital health and AIStrong governance, cautious adoptionAdvanced digital infrastructure and real-time AI deploymentCross-validation of AI-based tools and implementation pathwaysGenetic backgroundPredominantly European ancestryPredominantly East Asian ancestryPopulation-specific immune responsesDrug metabolismLower prevalence of key CYP variantsHigher prevalence of CYP polymorphismsImpacts dosing and toxicityMetabolic profilesHigher obesity and insulin resistanceDifferent body compositionAlters sepsis trajectoriesMicrobial ecologyDistinct resistance patternsDistinct pathogen distributionInfluences treatment responseGuideline developmentConsensus-drivenIncreasing guideline adoption with rapid pragmatic implementationOpportunity for bidirectional learningData interoperabilityStrong regulatory governance and emerging federated infrastructuresLarge-scale EHR systems requiring harmonization across coding and language systemsCommon data models are essential to move from data sharing to true interoperabilityThis table summarizes key contrasts between European and Chinese critical care systems, research infrastructures, and population characteristics that are relevant to sepsis biology and clinical investigation. Differences across healthcare system maturity, patient volume, digital health and AI integration, genetic background, drug metabolism, metabolic profiles, microbial ecology, and guideline development are highlighted to illustrate how these regions provide complementary environments for sepsis research. Together, these features underscore the potential value of Europe–China collaboration for identifying universal and population-specific sepsis phenotypes and for advancing globally relevant precision critical care.AI, Artificial intelligence; ICU, Intensive care unit. Complementary strengths and population-level differences relevant to sepsis research in Europe and China. This table summarizes key contrasts between European and Chinese critical care systems, research infrastructures, and population characteristics that are relevant to sepsis biology and clinical investigation. Differences across healthcare system maturity, patient volume, digital health and AI integration, genetic background, drug metabolism, metabolic profiles, microbial ecology, and guideline development are highlighted to illustrate how these regions provide complementary environments for sepsis research. Together, these features underscore the potential value of Europe–China collaboration for identifying universal and population-specific sepsis phenotypes and for advancing globally relevant precision critical care. AI, Artificial intelligence; ICU, Intensive care unit. A balanced Europe–China collaboration also requires recognition of ongoing challenges in both settings. In Europe, mature governance structures and high methodological standards coexist with fragmented healthcare systems, heterogeneous national regulations, and variable interpretations of data protection frameworks such as the General Data Protection Regulation. These factors can slow cross-border data aggregation and limit the speed of large-scale implementation. In China, the size and diversity of the healthcare system create different challenges, including variation between highly advanced urban academic centers and smaller regional or rural hospitals, where resources, staffing, digital infrastructure, and standardization of care may differ.[7] These limitations do not weaken the case for collaboration; rather, they define its purpose. The objective should be bidirectional learning: Europe can contribute experience in harmonization, trial governance, and reproducibility, while China can contribute implementation speed, scale, and rapidly expanding clinical research networks. Why Sepsis Phenotypes May Not Travel Well One of the central challenges in contemporary sepsis research is the widespread assumption that biological phenotypes identified in one population are universally applicable. Growing evidence suggests that this assumption is flawed. The host response to infection is shaped by a complex interplay of genetic background, metabolic pathways, immune regulation, prior microbial exposure, and environmental factors, all of which vary substantially across populations and healthcare systems. These differences influence not only susceptibility to infection and patterns of organ dysfunction, but also the timing, magnitude, and resolution of inflammatory and immunosuppressive responses. As a result, sepsis phenotypes derived from cohorts in Western countries may not fully capture the biological diversity observed in Asian populations, and may carry different prognostic or therapeutic implications. Without cross-population validation, phenotype-driven strategies risk limited generalizability and may fail to deliver the anticipated benefits of precision medicine in sepsis. Genetic and Immunological Variability A key biological driver of these population-specific differences lies in host genetics and immune regulation. Population-level variation in immune-related genes is well established, with significant differences observed between different populations. Polymorphisms affecting innate immune sensing, cytokine production, and antigen presentation influence how infections are detected, amplified, and resolved. In particular, variants in genes involved in toll-like receptor signaling, inflammasome activation, and cytokine regulation can modulate susceptibility to infection, the magnitude of the inflammatory response, and the trajectory toward organ dysfunction. Differences in HLA haplotypes may further shape adaptive immune responses and contribute to variability in post-sepsis immune suppression and recovery. Genomic endotyping has fundamentally reshaped our understanding of sepsis by demonstrating that distinct host immune expression signatures are associated with divergent clinical trajectories and differential responses to therapy, highlighting the central role of host biology in determining outcome. Importantly, emerging genomic studies across diverse patient populations suggest that immune response patterns defined in one host group may not fully capture the biological spectrum present in others, reinforcing concerns about the universal applicability of sepsis endotypes derived from limited or homogeneous cohorts. From Data Sharing to Interoperability: The Current Landscape of Global Precision Sepsis Pathogen distribution and antimicrobial resistance patterns differ substantially between regions. Large Chinese surveillance studies have documented distinct pathogen prevalence and resistance mechanisms compared with European cohorts, particularly among Gram-negative organisms.[8] Prior antimicrobial exposure, endemic resistance, and healthcare-associated microbiology influence sepsis trajectories and may confound phenotype definitions based purely on host markers. Global epidemiological analyses further highlight pronounced regional variation in sepsis incidence and outcomes. Taken together, these factors argue strongly against a one-size-fits-all approach to sepsis phenotyping. Cross-continental collaboration is essential to distinguish universal biological signals from population-specific patterns.[9] The current landscape of critical care data sharing already demonstrates both the potential and the limitations of this approach. Open-access databases have transformed sepsis and ICU research by enabling external validation, reproducible modeling, benchmarking of prediction tools, and discovery of data-driven phenotypes across large patient cohorts.[10] These resources have shown that collaborative critical care datasets can accelerate hypothesis generation and model development, but they have also exposed an important limitation: models and phenotypes derived in one health system may lose calibration, discrimination, or biological meaning when transported to another. Studies of clinical sepsis subphenotypes, including the α, β, γ, and δ phenotypes, have provided an important proof of concept for phenotype discovery, but their clinical utility depends on repeated validation across different populations, healthcare systems, microbial ecologies, and treatment practices. However, international collaboration cannot rely on data being merely “shared.” For sepsis research to become genuinely interoperable, local electronic health record data must be mapped into harmonized structures using common data models and standard vocabularies. This is particularly important for Europe–China collaboration, where differences in language, clinical documentation, laboratory coding, medication dictionaries, microbiology reporting, billing systems, and diagnostic classifications may otherwise create hidden sources of bias.[11] Apparent equivalence between variables may conceal major differences in meaning, timing, granularity, or clinical use. Common data models, such as the Observational Medical Outcomes Partnership model, offer a practical route to map local terminologies onto standardized concepts while allowing institutions to retain control of their own data.[12] In this context, federated analytics should be understood not simply as a privacy-preserving solution, but as an interoperability framework that enables comparable definitions, reproducible phenotyping, and reciprocal validation across jurisdictions.[13] If sepsis phenotypes are context-dependent, then validation across populations becomes a prerequisite for progress. This requires shared data, but not necessarily shared databases. Federated data models, harmonized definitions, and common analytic frameworks allow institutions and countries to collaborate while respecting data governance, privacy, and sovereignty. Europe has extensive experience with regulatory frameworks, ethical oversight, and data standardization. China has demonstrated the feasibility of large-scale, real-time data integration and AI-assisted analysis. Combining these strengths enables a collaborative model in which hypotheses generated in one region can be tested, refined, and validated in another.[14] Such collaboration offers several advantages: identification of phenotypes consistent across genetic and healthcare contexts, recognition of region-specific phenotypes requiring tailored interventions, more inclusive clinical trial design, and development of adaptive guidelines that reflect biological diversity rather than assuming homogeneity. A Call for Coordinated Global Discovery Sepsis is a global syndrome, yet much of the evidence guiding its management remains geographically siloed. Europe and China are uniquely positioned to change this. By combining methodological maturity with technological scale, and by embracing biological diversity rather than ignoring it, collaborative sepsis research can move beyond descriptive epidemiology toward actionable precision medicine.[15] This collaboration is not about harmonizing practice for its own sake. It is about understanding where harmonization is appropriate and where adaptation is necessary. It is about recognizing that a phenotype defined in Berlin or Barcelona may not fully capture the biology of a patient in Beijing or Shanghai, and that both perspectives are needed to advance care. Conclusions Sepsis is a global syndrome shaped by profound biological, epidemiological, and health-system heterogeneity, and progress toward precision critical care will remain limited if discovery and validation are confined within regional boundaries. Europe–China collaboration offers a uniquely powerful framework to address this challenge by combining methodological rigor with scale, speed, and advanced digital infrastructure, while explicitly accounting for population-level differences in genetics, metabolism, microbial ecology, and care delivery. Such collaboration enables the identification of truly universal sepsis signals, the recognition of region-specific phenotypes, and the design of adaptive, biologically informed interventions rather than one-size-fits-all solutions. Federated data sharing, harmonized analytic approaches, and reciprocal validation across populations provide a pragmatic and ethical path forward. Ultimately, embracing cross-continental partnership is not optional but essential if precision sepsis care is to become clinically meaningful, globally relevant, and equitable for the diverse populations affected by this complex syndrome. Funding No specific funding was received for the preparation of this manuscript. The authors declare that no funding body had any role in the conceptualization, design, interpretation, decision to publish, or preparation of the manuscript. CRediT authorship contribution statement Ignacio Martin-Loeches: Writing – review & editing, Writing – original draft, Resources, Methodology, Conceptualization. Yan Kang: Writing – review & editing. Jean-Louis Teboul: Writing – review & editing. Conflict of Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ignacio Martin-Loeches reports personal fees and/or non-financial support from Thermofisher Scientific, bioMérieux, MSD, Gilead Sciences, Mundipharma, and Pfizer, outside the submitted work. Yan Kang and Jean-Louis Teboul declare no competing interests. Managing Editor: Jingling Bao References